Kallistatin as a Potential Marker of Therapeutic Response During Alpha-Lipoic Acid Treatment in Diabetic Patients with Sensorimotor Polyneuropathy
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms252413276 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Marcell Hernyák und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary. Hauptthemen laut MEDLINE: Thioctic Acid, Serpins, Diabetic Neuropathies, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research, Development and Innovation Office-NKFIH, National Research, Development and Innovation Fund, Eötvös Loránd Research Network.
Abstract (Originalsprache)
Diabetic sensorimotor neuropathy (DSPN) is strongly associated with the extent of cellular oxidative stress and endothelial dysfunction in type 2 diabetes (T2DM). Alpha-lipoic acid (ALA) attenuates the progression of DSPN through its antioxidant and vasculoprotective effects. Kallistatin has antioxidant and anti-inflammatory properties. We aimed to evaluate changes in kallistatin levels and markers of endothelial dysfunction in patients with T2DM and DSPN following six months of treatment with 600 mg/day of ALA. A total of 54 patients with T2DM and DSPN and 24 control patients with T2DM but without neuropathy participated in this study. The serum concentrations of kallistatin, ICAM-1, VCAM-1, oxLDL, VEGF, ADMA, and TNF-alpha were measured by an ELISA. Peripheral sensory neuropathy was assessed with neuropathy symptom questionnaires and determination of the current perception threshold. After ALA treatment, the level of kallistatin significantly decreased, as well as the levels of TNF-alpha and ADMA. Changes in kallistatin levels were positively correlated with changes in oxLDL. The improvement in DSPN symptoms following ALA treatment showed a positive correlation with changes in kallistatin, VEGF, oxLDL, and ADMA levels. Based on our results, kallistatin could represent a potential new biomarker for assessing therapeutic response during ALA treatment in patients with DSPN.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary.
- Doctoral School of Health Sciences, University of Debrecen, H-4032 Debrecen, Hungary.
- Institute of Health Studies, Faculty of Health Sciences, University of Debrecen, H-4032 Debrecen, Hungary.
- ELKH-UD Vascular Pathophysiology Research Group 11003, University of Debrecen, H-4032 Debrecen, Hungary.
ORCID-Profile: Hajnalka Lőrincz, Mariann Harangi
Förderung
- National Research, Development and Innovation Office-NKFIH
- National Research, Development and Innovation Fund
- Eötvös Loránd Research Network
- National Research, Development and Innovation Office (NKFIH)
- Ministry of Innovation and Technology of Hungary
Zitieren
APA
Hernyák, M., Tóth, L. I., Csiha, S., Molnár, Á., Lőrincz, H., Paragh, G., Harangi, M., & Sztanek, F. (2024). Kallistatin as a Potential Marker of Therapeutic Response During Alpha-Lipoic Acid Treatment in Diabetic Patients with Sensorimotor Polyneuropathy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252413276
Vancouver
Hernyák M, Tóth LI, Csiha S, Molnár Á, Lőrincz H, Paragh G, et al. Kallistatin as a Potential Marker of Therapeutic Response During Alpha-Lipoic Acid Treatment in Diabetic Patients with Sensorimotor Polyneuropathy. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252413276
BibTeX
@article{Hernyk2024,
author = {Hernyák, Marcell and Tóth, László Imre and Csiha, Sára and Molnár, Ágnes and Lőrincz, Hajnalka and Paragh, György and Harangi, Mariann and Sztanek, Ferenc},
title = {Kallistatin as a Potential Marker of Therapeutic Response During Alpha-Lipoic Acid Treatment in Diabetic Patients with Sensorimotor Polyneuropathy},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms252413276}
}
EUVIMED